Hepatitis/MASH

Much higher rate of patients in real world discontinuing high priced treatment than during clinical studies.

Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.

Data indicates that a simeprevir-based therapy is efficacious in patients with HIV-1/HCV genotype 1 coinfection.

A recent study published in the journal Hepatology indicates that as many as 11% of baby boomers had a positive test result for presence of anti-HCV antibodies.

Study finds HIV suppression reduces hepatitis C viral replication over time.

New drugs to treat hepatitis C herald a new era of higher cure rates, but with these new treatment options comes an increased need for patient support and adherence counseling.

With the recent approval of new hepatitis C treatments, payers are increasingly concerned with controlling costs in this category through policies that may affect treatment decisions.

The high cost of treating hepatitis C with sofosbuvir (Sovaldi) has received a lot of attention in the literature.

A multicenter study will examine whether a drug used to treat rheumatoid arthritis can improve kidney transplant patients' health.

Screening of newborn children for hepatitis C and new, more effective hepatitis C treatments may virtually eliminate the disease in the United States by 2036.

New therapies can cost patients $84,000 for a standard 12-week course of therapy.

Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.

A study finds that patients co-infected with hepatitis C and HIV who are receiving antiretroviral therapy are 80% more likely to have serious liver disease than those with hepatitis C alone.

The cost of specialty drugs is driving increases in overall unit cost, according to an annual Catamaran Corporation report.

An analysis of several phase III clinical trials suggests that health-related quality-of-life scores decrease less when patients receive sofosbuvir therapy than interferon therapy.

Hepatitis C treatment guidelines have been updated to include several new drugs.